

Publication record Dr Florian Gebauer

Total publications 71

Cumulative IF 267, citations 2248, h index 22

First authorship

1. Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
Gebauer F, Damanakis AI, Popp F, Quaas A, Kütting F, Lutz K, Held S, Deuß B, Göser T, Waldschmidt D, Bruns C. *BMC Cancer*. 2021 Nov 18;21(1):1239.
IF 4.4
2. Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma.
Gebauer F, Krämer M, Bruns C, Schlößer HA, Thelen M, Lohneis P, Schröder W, Zander T, Alakus H, Buettner R, Loeser H, Quaas A. *J Cancer Res Clin Oncol*. 2020 Sep;146(9):2319-2327.
IF 3.08
3. Claudin 18.2 expression in esophageal adenocarcinoma and its potential impact on future treatment strategies.
Moentenich V, Gebauer F, Comut E, Tuchscherer A, Bruns C, Schroeder W, Buettner R, Alakus H, Loeser H, Zander T, Quaas A. *Oncol Lett*. 2020 Jun;19(6):3665-3670.
IF 1,55
4. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS* and Gebauer F*, Krämer M, Alakus H, Berth F, Chon SH, Schiffmann L, Zander T, Büttner R, Hölscher AH, Bruns CJ, Quaas A, Loeser H. *BMC Cancer*. 2019 Jan 8;19(1):38.
IF 3.42
5. Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance?
Gebauer F, Kemper M, Sauter G, Prehm P, Schumacher U. *PLoS One*. 2017 Jun 5;12(6):e0178703.
IF 2.80
6. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis.
Tachezy M and Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, Perinel J, Adham M, Dervenis C, Agalianos C, Malleo G, Maggino L, Stein A, Izbicki JR, Bockhorn M. *Surgery*. 2016 Jul;160(1):136-144.
IF 4,4

7. Establishment and Characterization of a Pair of Patient-derived Human Non-small Cell Lung Cancer Cell Lines from a Primary Tumor and Corresponding Lymph Node Metastasis.
Gebauer F, Wicklein D, Tachezy M, Grob T, Steinemann D, Manukjan G, Göhring G, Schlegelberger B, Maar H, Izbicki JR, Bockhorn M, Schumacher U. *Anticancer Res.* 2016 Apr;36(4):1507-18.
IF 1,93
8. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer.
Gebauer F, Wicklein D, Horst J, Sundermann P, Maar H, Streichert T, Tachezy M, Izbicki JR, Bockhorn M, Schumacher U. *PLoS One.* 2014 Nov 19;9(11):e113023
IF 4,4
9. Resection Margin Clearance in Pancreatic Cancer After Implementation of the Leeds Pathology Protocol (LEPP): Clinically Relevant or Just Academic? Gebauer F* and Tachezy M*, Vashist YK, Marx AH, Yekebas E, Izbicki JR, Bockhorn M. *World J Surg.* 2014 Oct 1 IF 2,77
10. Tenascin-C serum levels and its prognostic power in non-small cell lung cancer.
Gebauer F, Gelis S, Zander H, Meyer KF, Wolters-Eisfeld G, Izbicki JR, Bockhorn M, Tachezy M. *Oncotarget.* 2016 Apr 12;7(15):20945-52.
IF 5,16
11. Serum EpCAM Expression in Pancreatic Cancer.
Gebauer F, Struck L, Tachezy M, Vashist Y, Wicklein D, Schumacher U, Izbicki JR, Bockhorn M. *Anticancer Res.* 2014 Sep;34(9):4741-6.
IF 1.93
12. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).
Tachezy M* and Gebauer F*, Petersen C, Arnold D, Trepel M, Wegscheider K, Schafhausen P, Bockhorn M, Izbicki JR, Yekebas E. *BMC Cancer.* 2014 Jun 7;14:411.
IF 3.28
13. Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp--/rag2—mice
Gebauer F, Wicklein D, Stübke K, Nehmann N, Schmidt A, Salamon J, Peldschus K, Nentwich MF, Adam G, Tolstonog G, Bockhorn M, Izbicki JR, Wagener C, Schumacher U *Gut.* 2012 Apr 5.
IF 17.93
14. Options and Limitations in Applying the Fistula Classification by the International Study Group for Pancreatic Fistula
Gebauer F, Kloth K, Tachezy M, Vashist YK, Cataldegirmen G, Izbicki JR, Bockhorn M *Ann Surg.* 2012 Jul;256(1):130-8.
IF 9.20

15. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR, Bockhorn M. *J Surg Oncol*. 2011 Aug 1;104(2):140-5. IF 3.11
16. Chronic pancreatitis complicated by cavernous transformation of the portal vein: contraindication to surgery? Bockhorn M* and Gebauer F*, Bogoevski D, Molmenti E, Cataldegirmen G, Vashist YK, Yekebas EF, Izbicki JR, Mann O. *Surgery*. 2011 Mar;149(3):321-8. IF 3.47

Last authorship

1. Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma. Damanakis AI, Wahler I, Fuchs H, Löser H, Schröder W, Zander T, Chon SH, Bruns C, Quaas A, Gebauer F. *Sci Rep*. 2022 Dec 1;12(1):20745. IF 5.13
2. Influence of patient sex on outcomes after pancreatic surgery: multicentre study. Damanakis AI, Toader J, Wahler I, Plum P, Quaas A, Ernst A, Popp F, Gebauer F*, Bruns C.* *Br J Surg*. 2022 Jul 15;109(8) IF 6.9
3. Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus. Schoemmel M, Loeser H, Kraemer M, Wagener-Rydzek S, Hillmer A, Bruns C, Thelen M, Schröder W, Zander T, Lechner A, Buettner R, Schlösser H, Gebauer F, Quaas A; Gastrointestinal Cancer Group Cologne (GCGC). *Clin Transl Oncol*. 2021 Aug;23(8):1601-1610. IF 2.74
4. GATA binding protein 6 (GATA6) is co-amplified with PIK3CA in patients with esophageal adenocarcinoma and is linked to neoadjuvant therapy. Plum PS, Löser H, Zander T, Essakly A, Bruns CJ, Hillmer AM, Alakus H, Schröder W, Büttner R, Gebauer F, Quaas A. *J Cancer Res Clin Oncol*. 2021 Apr;147(4):1031-1040. IF 4.55
5. Integrin alpha V (ITGAV) expression in esophageal adenocarcinoma is associated with shortened overall-survival. Loeser H, Scholz M, Fuchs H, Essakly A, Damanakis AI, Zander T, Büttner R, Schröder W, Bruns C, Quaas A, Gebauer F. *Sci Rep*. 2020 Oct 27;10(1):18411. IF 5.13
6. Y Chromosome Loss is a Frequent Event in Barrett's Adenocarcinoma and Associated with Poor Outcome. Loeser H, Wölwer CB, Alakus H, Chon SH, Zander T, Buettner R, Hillmer AM, Bruns CJ, Schroeder W, Gebauer F* and Quaas A*. *Cancers (Basel)*. 2020 Jun 30;12(7):1743.

IF 6.10

7. Dickkopf-2 (DKK2) as Context Dependent Factor in Patients with Esophageal Adenocarcinoma.
Schiffmann LM, Loeser H, Jacob AS, Maus M, Fuchs H, Zhao Y, Tharun L, Essakly A, Iannos Damanakis A, Zander T, Büttner R, Schröder W, Bruns C, Quaas A, Gebauer F. *Cancers (Basel)*. 2020 Feb 14;12(2).
IF 6.10
8. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S, Bork J, Essakly A, Alakus H, Buettner R, Hillmer AM, Bruns C, Schroeder W, Zander T, Loeser H, Gebauer F* and Quaas A*. *BMC Cancer*. 2020 Jan 6;20(1):12.
IF 3.42
9. Proposal for a definition of "Oligometastatic disease in pancreatic cancer".
Damanakis AI, Ostertag L, Waldschmidt D, Kütting F, Quaas A, Plum P, Bruns CJ, Gebauer F* and Popp F*. *BMC Cancer*. 2019 Dec 30;19(1):1261.
IF 3.42
10. PIK3CA and KRAS Amplification in Esophageal Adenocarcinoma and their Impact on the Inflammatory Tumor Microenvironment and Prognosis.
Essakly A, Loeser H, Kraemer M, Alakus H, Chon SH, Zander T, Buettner R, Hillmer AM, Bruns CJ, Schroeder W, Gebauer F* and Quaas A*. *Transl Oncol*. 2019 Dec 19;13(2):157-164.
IF 3.31
11. Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma.
Schiffmann LM, Göbel H, Löser H, Schorn F, Werthenbach JP, Fuchs HF, Plum PS, Bludau M, Zander T, Schröder W, Bruns CJ, Kashkar H, Quaas A, Gebauer F. *BMC Cancer*. 2019 May 31;19(1):531.
IF 3.42
12. p53 overexpression is a prognosticator of poor outcome in esophageal cancer.
Melling N, Norrenbrock S, Kluth M, Simon R, Hube-Magg C, Steurer S, Hinsch A, Burandt E, Jacobsen F, Wilczak W, Quaas A, Bockhorn M, Grupp K, Tachezy M, Izbicki J, Sauter G, Gebauer F. *Oncol Lett*. 2019 Apr;17(4):3826-3834.
IF 1.55

Co-authorships

1. FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.
Albin J, Fahrig L, Siemanowski J, Rehkaemper J, Gebauer F, Zander T, Buettner R, Bruns CJ, Schroeder W, Alakus H, Hieggelke L, Quaas A. *J Cancer Res Clin Oncol.* 2022 Nov 23.
IF 4.3
2. Fructose-1,6-bisphosphatase 1 (FBP1) is an independent biomarker associated with a favorable prognosis in esophageal adenocarcinoma.
Damanakis A, Plum PS, Gebauer F, Schröder W, Büttner R, Zander T, Bruns CJ, Quaas A. *J Cancer Res Clin Oncol.* 2022 Sep;148(9):2287-2293.
IF 4.3
3. Long-Term Outcome After Histopathological Complete Response with and Without Nodal Metastases Following Multimodal Treatment of Esophageal Cancer.
Schroeder W, Ghadimi MPH, Schloesser H, Loeser H, Schiller P, Zander T, Gebauer F, Fuchs H, Quaas A, Bruns CJ. *Ann Surg Oncol.* 2022 Apr 11.
IF 5.3
4. International Tumor Budding Consensus Conference criteria determine the prognosis of oesophageal adenocarcinoma with poor response to neoadjuvant treatment.
Lohneis P, Rohmann J, Gebauer F, Hieggelke L, Bruns C, Schröder W, Büttner R, Löser H, Quaas A. *Pathol Res Pract.* 2022 Apr;232:153844.
IF 3.2
5. Expression of Neighbor of Punc E11 (NOPE) in early stage esophageal adenocarcinoma is associated with reduced survival.
Kütting F, Gebauer F, Zweerink S, Krämer L, Schramm C, Quaas A, Bruns C, Goeser T, Nierhoff D. *Sci Rep.* 2022 Mar 4;12(1):3584
IF 4.9
6. A new hybrid stent using endoscopic vacuum therapy in treating esophageal leaks: a prospective single-center experience of its safety and feasibility with mid-term follow-up.
Chon SH, Scherdel J, Rieck I, Lorenz F, Dratsch T, Kleinert R, Gebauer F, Fuchs HF, Goeser T, Bruns CJ. *Dis Esophagus.* 2021 Sep 24.
IF 3.43
7. Occurrence of High Microsatellite-Instability/Mismatch Repair Deficiency in Nearly 2,000 Human Adenocarcinomas of the Gastrointestinal Tract, Pancreas, and Bile Ducts: A Study From a Large German Comprehensive Cancer Center.
Quaas A, Rehkaemper J, Rueschoff J, Pamuk A, Zander T, Hillmer A, Siemanowski J, Wittig J, Buettner R, Plum P, Popp F, Gebauer F, Bruns CJ, Loeser H, Alakus H, Schoemig-Markiefka B. *Front Oncol.* 2021 Jul 22;11:569475.
IF 4.84
8. Gastrointestinal function testing model using a new laryngopharyngeal pH probe (Restech) in patients after Ivor-Lewis esophagectomy.

Babic B, Müller DT, Gebauer F, Schiffmann LM, Datta RR, Schröder W, Bruns CJ, Leers JM, Fuchs HF. *World J Gastrointest Oncol* 2021 Jun 15;13(6):612-624.
IF 3.39

9. Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression.
Kemper M, Schiecke A, Maar H, Nikulin S, Poloznikov A, Galatenko V, Tachezy M, Gebauer F, Lange T, Riecken K, Tonevitsky A, Aigner A, Izbicki J, Schumacher U, Wicklein D. *J Exp Clin Cancer Res*. 2021 Jun 26;40(1):214. doi: 10.1186/s13046-021-01946-2.
IF 11.16
10. Endoscopic vacuum therapy versus stent treatment of esophageal anastomotic leaks (ESOLEAK): study protocol for a prospective randomized phase 2 trial.
Tachezy M, Chon SH, Rieck I, Kantowski M, Christ H, Karstens K, Gebauer F, Goeser T, Rösch T, Izbicki JR, Bruns CJ. *Trials*. 2021 Jun 2;22(1):377
IF 2.05
11. Aldo-Keto Reductase 1C3 Mediates Chemotherapy Resistance in Esophageal Adenocarcinoma via ROS Detoxification.
Zhou C, Wang Z, Li J, Wu X, Fan N, Li D, Liu F, Plum PS, Hoppe S, Hillmer AM, Quaas A, Gebauer F, Chon SH, Bruns CJ, Zhao Y. *Cancers (Basel)*. 2021 May 16;13(10):2403.
IF 6.64
12. Sex-specific prognostic effect of CD66b-positive tumor-infiltrating neutrophils (TANs) in gastric and esophageal adenocarcinoma.
Quaas A, Pamuk A, Klein S, Quantius J, Rehkaemper J, Barutcu AG, Rueschoff J, Zander T, Gebauer F, Hillmer A, Buettner R, Schroeder W, Bruns CJ, Löser H, Schoemig-Markiefka B, Alakus H. *Gastric Cancer*. 2021 May 19.
IF 7.4
13. Interferon-Induced Protein With Multiple Tetratricopeptide Repeats 3 Is Associated With Response to Chemotherapy and Recurrence but Not With Survival.
Popp MC, Klippstein M, Lohneis P, Kalinski T, Li J, Quaas A, Bludau M, Wang Z, Waldschmidt D, Kunzmann V, Damanakis A, Gebauer F, Zhao Y, Bruns CJ, Popp FC. *Pancreas*. 2020 Nov/Dec;49(10):1307-1314
IF 2.1
14. Tumor budding assessed according to the criteria of the International Tumor Budding Consensus Conference determines prognosis in resected esophageal adenocarcinoma.
Lohneis P, Hieggelke L, Gebauer F, Ball M, Bruns C, Büttner R, Löser H, Quaas A. *Virchows Arch*. 2020 Aug 6.
IF 2.84
15. Mesothelin expression in esophageal adenocarcinoma and squamous cell carcinoma and its possible impact on future treatment strategies.
Moentenich V, Comut E, Gebauer F, Tuchscherer A, Bruns C, Schroeder W, Buettner R, Alakus H, Loeser H, Zander T, Quaas A. *Ther Adv Med Oncol*. 2020 May 20;12
IF 6.85

16. Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Rydzek S, Schoemmel M, Kraemer M, Bruns C, Schroeder W, Zander T, Gebauer F, Alakus H, Merkelbach-Bruse S, Buettner R, Loeser H, Thelen M, Schlößler HA, Quaas A. *Cancer Immunol Immunother.* 2020 Apr;69(4):523-533.
IF 4.85
17. True single-port cholecystectomy with ICG cholangiography through a single 15-mm trocar using the new surgical platform "symphonX": first human case study with a commercially available device.
Datta RR, Dieplinger G, Wahba R, Kleinert R, Thomas M, Gebauer F, Schiffmann L, Stippel DL, Bruns CJ, Fuchs HF. *Surg Endosc.* 2019 Oct 28.
IF 3.74
18. The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma.
Loeser H, Kraemer M, Gebauer F, Bruns C, Schröder W, Zander T, Persa OD, Alakus H, Hoelscher A, Buettner R, Lohneis P, Quaas A. *Oncoimmunology.* 2019 Feb 27;8(5):e1581546.
IF 5.5
19. High levels of RAI3 expression is linked to shortened survival in esophageal cancer patients.
El Gammal AT, Melling N, Reeh M, Gebauer F, Mann O, Perez D, Bockhorn M, Bachmann K, Izbicki JR, Grupp K. *Exp Mol Pathol.* 2019 Jan 29;107:51-56.
IF 2.56
20. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM, Fritsch M, Gebauer F, Günther SD, Stair NR, Seeger JM, Thangarajah F, Dieplinger G, Bludau M, Alakus H, Göbel H, Quaas A, Zander T, Hilberg F, Bruns CJ, Kashkar H, Coutelle O. *Br J Cancer.* 2019 Jan;120(1):69-78.
IF 5.92
21. Genomic Characterization of TP53-Wild-Type Esophageal Carcinoma.
Quaas A, Heydt C, Gebauer F, Alakus H, Loeser H, Buettner R, Hillmer A, Bruns C, Merkelbach-Bruse S, Zander T, Frommolt P. *Transl Oncol.* 2019 Jan;12(1):154-161.
IF 3.07
22. Improved risk stratification by circulating tumor cell counts in pancreatic cancer.
Effenberger KE, Schroeder C, Hanssen A, Wolter S, Eulenburger C, Tachezy M, Gebauer F, Izbicki JR, Pantel K, Bockhorn M. *Clin Cancer Res.* 2018 Mar 20.
IF 9,62
23. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
Yang S, Che SP, Kurywchak P, Tavormina JL, Gansmo LB, Correa de Sampaio P, Tachezy M, Bockhorn M, Gebauer F, Haltom AR, Melo SA, LeBleu VS, Kalluri R. *Cancer Biol Ther.* 2017 Mar 4;18(3):158-165.
IF 3,29

24. HRG/HER2/HER3 signaling promotes AhR-mediated Memo-1 expression and migration in colorectal cancer.
Bogoevska V, Wolters-Eisfeld G, Hofmann BT, El Gammal AT, Mercanoglu B, Gebauer F, Vashist YK, Bogoevski D, Perez D, Gagliani N, Izbicki JR, Bockhorn M, Gungör C. *Oncogene*. 2017 Apr 27;36(17):2394-2404.
IF 7,51
25. Prognostic Impact of Activated Leucocyte Cell Adhesion Molecule (ALCAM/CD166) in Infantile Neuroblastoma.
Wachowiak R, Mayer S, Kaifi J, Gebauer F, Izbicki JR, Lacher M, Bockhorn M, Tachezy M. *Anticancer Res*. 2016 Aug;36(8):3991-5.
IF 1,93
26. Diverse prognostic value of the GTn promoter polymorphism in squamous cell and adeno carcinoma of the oesophagus.
Ghadban T, Miro JT, Trump F, Tsui TY, Uzunoglu FG, Reeh M, Gebauer F, Bachmann K, Wellner U, Kalinin V, Pantel K, Izbicki JR, Vashist YK. *Clin Genet*. 2016 Oct;90(4):343-50.
IF 3,32
27. Perioperative CRP quantification for appendectomy: Clinically useful or a waste of money?
Tachezy M, Anusic I, Rothenhöfer S, Gebauer F, Izbicki JR, Bockhorn M. *Chirurg*. 2015 Sep;86(9):881-8. doi: 10.1007/s00104-014-2913-9. German.
IF 0,63
28. ABO Blood Group IgM Isoagglutinins interact with Tumor-associated O-glycan Structures in Pancreatic Cancer.
Hofmann BT, Stehr A, Dohrmann T, Gungor C, Herich L, Hiller J, Harder S, Ewald F, Gebauer F, Tachezy M, Precht C, Izbicki JR, Bockhorn M, Wagener C, Wolters-Eisfeld G. *Clin Cancer Res*. 2014 Oct 15.
IF 9,62
29. Prognostic impact of perineural, blood and lymph vessel invasion for esophageal cancer.
Tachezy M, Tiebel AK, Gebauer F, Kutup A, Tharun L, Pantel K, Izbicki JR, Vashist YK. *Histol Histopathol*. 2014 May 12.
IF 2.03
30. Aberrant Presentation of HPA-reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer.
Lange T, Kupfernagel M, Wicklein D, Gebauer F, Maar H, Brügge K, Müller I, Simon R, Schlomm T, Sauter G, Schumacher U. *Clin Cancer Res*. 2014 Feb 13.
IF 9,62
31. Activated leukocyte cell adhesion molecule (CD166); An 'Inert' cancer stem cell marker for non-small cell lung cancer? Tachezy M, Zander H, Wolters-Eisfeld G, Müller J, Wicklein D, Gebauer F, Izbicki JR, Bockhorn M. *Stem Cells*. 2014 Feb 5.
IF 5,59

32. CXCR7 expression in esophageal cancer.
Tachezy M, Zander H, Gebauer F, von Loga K, Pantel K, Izbicki JR, Bockhorn M. *J Transl Med.* 2013 Sep 30;11:238.
IF 3,78
33. Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients.
Schröder C, Milde-Langosch K, Gebauer F, Schmid K, Mueller V, Wirtz RM, Meyer-Schwesinger C, Schlüter H, Sauter G, Schumacher U. *J Cancer Res Clin Oncol.* 2013 Oct;139(10):1745-55.
IF 3,08
34. Management of the difficult duodenal stump in penetrating duodenal ulcer disease: a comparative analysis of duodenojejunostomy with "classical" stump closure (Nissen-Bsteh).
Vashist YK, Yekebas EF, Gebauer F, Tachezy M, Bachmann K, König A, Kutup A, Izbicki JR. *Langenbecks Arch Surg.* 2012 Aug 19
IF 2,19
35. EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer.
Vashist YK, Trump F, Gebauer F, Kutup A, Güngör C, Kalinin V, Muddasar R, Vettorazzi E, Yekebas EF, Brandt B, Pantel K, Izbicki JR. *Target Oncol.* 2013 Feb 2
IF 3,03
36. ALCAM (CD166) expression and serum levels in pancreatic cancer.
Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR, Bockhorn M. *PLoS One.* 2012;7(6):e39018
IF 3,54
37. Activated leukocyte cell adhesion molecule (CD166)-Its prognostic power for colorectal cancer patients.
Tachezy M, Zander H, Gebauer F, Marx A, Kaifi JT, Izbicki JR, Bockhorn M. *J Surg Res.* 2012 Sep;177(1):e15-20
IF 2,18
38. Multivisceral resections in pancreatic cancer: identification of risk factors.
Burdelski CM, Reeh M, Bogoevski D, Gebauer F, Tachezy M, Vashist YK, Cataldegirmen G, Yekebas E, Izbicki JR, Bockhorn M. *World J Surg.* 2011 Dec;35(12):2756-63.
IF 2,67
39. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients.
Tachezy M, Effenberger K, Zander H, Minner S, Gebauer F, Vashist YK, Sauter G, Pantel K, Izbicki JR, Bockhorn M. *Int J Cancer.* 2011 Aug 19.
IF 6,51
40. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
Tachezy M, Zander H, Marx AH, Gebauer F, Rawnaq T, Kaifi JT, Sauter G, Izbicki

JR, Bockhorn M. J Surg Res. 2011 Oct;170(2):226-32
IF 2,18

41. Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer.
Vashist YK, Uzungolu G, Kutup A, Gebauer F, Koenig A, Deutsch L, Zehler O, Busch P, Kalinin V, Izbicki JR, Yekebas EF. J Surg Oncol. 2011 Sep 1;104(3):305-11.
IF 2,99
42. High surgical morbidity following distal pancreatectomy: still an unsolved problem.
Reeh M, Nentwich MF, Bogoevski D, Koenig AM, Gebauer F, Tachezy M, Izbicki JR, Bockhorn M. World J Surg. 2011 May;35(5):1110-7.
IF 2,67
43. Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil?
Tachezy M, Bockhorn M, Gebauer F, Vashist YK, Kaifi JT, Izbicki JR. J Gastrointest Surg. 2011 May;15(5):829-35
IF 2,96
44. Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
Tachezy M, Reichelt U, Melenberg T, Gebauer F, Izbicki JR, Kaifi JT. Histol Histopathol. 2010 Oct;25(10):1239-46.
IF 2,02

Review articles

1. Tumor biology and multidisciplinary strategies of oligometastasis in gastrointestinal cancers.
Zhao Y, Li J, Li D, Wang Z, Zhao J, Wu X, Sun Q, Lin PP, Plum P, Damanakis A, Gebauer F, Zhou M, Zhang Z, Schlösser H, Jauch KW, Nelson PJ, Bruns CJ. Semin Cancer Biol. 2019 Aug 21 Review.
IF 9.96
2. Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy.
Gebauer F, Damanakis AI, Bruns C. Chirurg. 2018 Mar 20. German.
IF 0.7
3. Pancreatic cancer and liver metastases: state of the art.
Bellon E, Gebauer F, Tachezy M, Izbicki JR, Bockhorn M. Updates Surg. 2016 Sep;68(3):247-25. Review
IF nicht verfügbar

Book chapters

1. Textbook of Pancreatic Cancer Principles and Practice of Surgical Oncology Kjetil Søreide, Stefan Stättner (Herausgeber) 2021 | 1st ed. 2021
Springer International Publishing
978-3-030-53785-2 (ISBN)
2. Erkrankungen des Pankreas: Evidenz in Diagnostik, Therapie und Langzeitverlauf
Hans Günther Beger (Herausgeber), Markus W. Büchler (Herausgeber), Henning Dralle (Herausgeber), Markus Lerch (Herausgeber), Peter Malfertheiner (Herausgeber), Joachim Mössner (Herausgeber), Jürgen F. Riemann (Herausgeber).
Springer Verlag, 1. Auflage Dezember 2013, ISBN-10: 364237963X

Case reports

1. Glomangioma of the lung: a case report and review of the literature.
Gebauer F, Quaas A, Izbicki JR, Vashist YK.
J Med Case Rep. 2014 Jan 3;8(1):5
2. Omental infarction in the postpartum period: a case report and a review of the literature.
Tachezy M, Grotelüschen R, Gebauer F, Marx AH, Izbicki JR, Kaifi JT.
J Med Case Reports. 2010 Nov 17;4:368.
3. Intrathoracic lesions in association with germ cell tumor of the testis
Mann O, Kleinhans H, Gebauer F, Kaifi J, Schurr PG, Izbicki JR, Strate TG.
Chirurg. 2008 Sep;79(9):874-6. German